CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Genzyme Corporation v. Sarepta Therapeutics, Inc.

1:24-cv-00882

Overview

Case Number 1:24-cv-00882
Filing Date 2024-07-26
Status Litigation filed
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:1 Patent Infringement
Jury Demand Plaintiff

Parties

Defendant

Sarepta Therapeutics Three, LLC Operating Company

Represented By

7 Attorneys Listed

Yihan Liu

Email: valentinaliu@quinnemanuel.com

Alexandra Kim

Email: alexandrakim@quinnemanuel.com

M. David Weingarten , Ph.D

Email: david.weingarten@finnegan.com

M. David Weingarten

Email: M.David.weingarten@finnegan.com

John D. Livingstone

Email: john.livingstone@finnegan.com

Derek James Fahnestock

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Megan Elizabeth Dellinger

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 351-9366

1201 North Market Street, P.O. Box 1347

Sarepta Therapeutics, Inc. Operating Company

Represented By

7 Attorneys Listed

Yihan Liu

Email: valentinaliu@quinnemanuel.com

Alexandra Kim

Email: alexandrakim@quinnemanuel.com

M. David Weingarten , Ph.D

Email: david.weingarten@finnegan.com

M. David Weingarten

Email: M.David.weingarten@finnegan.com

John D. Livingstone

Email: john.livingstone@finnegan.com

Derek James Fahnestock

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Megan Elizabeth Dellinger

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 351-9366

1201 North Market Street, P.O. Box 1347

Plaintiff

Genzyme Corporation NPE (Individual / Inventor)

Represented By

11 Attorneys Listed

Shyam Shanker

Email: shyam.shanker@dechert.com

Judah Bellin

Email: Judah.Bellin@dechert.com

Jonathan D. Loeb

Email: jonathan.loeb@dechert.com

Donald C. Vavala , III

Wilks Law, LLC

Tel: +1 (302) 225-0854
Fax: +1 (302) 225-0851

4250 Lancaster Pike, Suite 200

Sharon K. Gagliardi

Email: sharon.gagliardi@dechert.com

Noah M. Leibowitz

Email: noah.leibowitz@dechert.com

Martin J. Black

Email: martin.black@dechert.com

Katherine A. Helm

Email: khelm@dechert.com

Amanda K. Antons

Email: amanda.antons@dechert.com

Scott B. Czerwonka

Wilks Law, LLC

Tel: +1 (302) 230-5154
Fax: +1 (302) 225-0851

4250 Lancaster Pike, Ste 200

David E. Wilks

Wilks Law, LLC

Tel: +1 (302) 225-0858
Fax: +1 (302) 225-0851

4250 Lancaster Pike, Suite 200

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 6 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts Counterparts in force
🏛️
USPTO PTAB Trials 7 proceedings
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (6): 🇺🇸 US
Parallel Proceedings Across Jurisdictions (7 found):
PTAB: 7
USPTO PTAB Trial 2026-02-26
IPR2026-00270

Sarepta Therapeutics, Inc. et al. v. Genzyme Corporation et al.

U.S. Continuation Sibling (12298313)
Status: Institution Denied
USPTO PTAB Trial 2025-12-02
IPR2026-00168

Sarepta Therapeutics, Inc. et al. v. Genzyme Corporation et al.

U.S. Continuation Sibling (12123880)
Status: Institution Denied
USPTO PTAB Trial 2025-12-02
IPR2026-00167

Sarepta Therapeutics, Inc. et al. v. Genzyme Corporation et al.

U.S. Continuation Sibling (11698377)
Status: Institution Denied
USPTO PTAB Trial 2025-12-02
IPR2026-00166

Sarepta Therapeutics, Inc. et al. v. Genzyme Corporation et al.

U.S. Continuation Sibling (12298313)
Status: Terminated
USPTO PTAB Trial 2025-11-25
IPR2026-00150

Sarepta Therapeutics, Inc. et al. v. Genzyme Corporation et al.

U.S. Continuation Sibling (12031894)
Status: Trial Instituted
USPTO PTAB Trial 2025-11-25
IPR2026-00149

Sarepta Therapeutics, Inc. et al. v. Genzyme Corporation et al.

Asserted Patent
Status: Institution Denied
USPTO PTAB Trial 2025-06-26
IPR2025-01195

Sarepta Therapeutics, Inc. et al. v. Genzyme Corporation et al.

U.S. Continuation Sibling (7704721)
Status: Discretionary Denial
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

7 Patents

There are 7 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US9051542
Compositions and methods to prevent AAV vector aggregation
Filed: 2010-03-19
Issued: 2015-06-09
Active (3.3 yrs remaining)
Expires: 2030-03-19
US7704721
Compositions and methods to prevent AAV vector aggregation
Filed: 2005-06-01
Issued: 2010-04-27
Expired (Term Ended)
Expires: 2025-06-01
US12031894
Analytical ultracentrifugation for characterization of recombinant viral particles
Filed: 2023-11-20
Issued: 2024-07-09
Active (17.0 yrs remaining)
Expires: 2043-11-20
US12013326
Analytical ultracentrifugation for characterization of recombinant viral particles
Filed: 2023-11-10
Issued: 2024-06-18
Active (17.0 yrs remaining)
Expires: 2043-11-10
US11698377
Methods for detecting AAV
Filed: 2017-08-14
Issued: 2023-07-11
Active (11.7 yrs remaining) +359d PTA
Expires: 2038-08-08

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Active Threat

Active Threat — Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

52

Dispositive

3

Granted

3

Denied

0

Pending / Review

34

Motions by Category

Motion to Dismiss 3 Procedural / Extension Motion 19 Claim Construction / Markman Filing 30

Key Dispositive Motions & Rulings

Motion to Dismiss Pending
SO ORDERED, re 22 Stipulation and Proposed Order to Extend Time (*Reset Briefing Schedule: re 19 Partial Motion to Dismiss. Answering Brief due 11/21/2024, Repl...
Entry #— • 2024-11-13
Motion to Dismiss Pending / Under Review
PARTIAL Motion to Dismiss - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.. (Dellinger, Megan) Modified on 10/31/2024 (nms). (Entered: 10/...
Entry #19 • 2024-10-31 Document →
Motion to Dismiss Pending / Under Review
OPENING BRIEF in Support re 19 Partial Motion to Dismiss, filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.. Answering Brief/Response due dat...
Entry #20 • 2024-10-31 Document →
Claim Construction / Markman Filing Pending / Under Review
Letter to Honorable Richard G. Andrews, from D. Charles Vavala, III, regarding proposed Claim Construction Order. (Attachments: # 1 Proposed Order)(Vavala, Dona...
Entry #161 • 2026-04-27 Document →
Claim Construction / Markman Filing Pending / Under Review
CLAIM CONSTRUCTION ORDER. Signed by Judge Richard G. Andrews on 4/27/2026. (aas) (Entered: 04/27/2026)
Entry #162 • 2026-04-27 Document →
Claim Construction / Markman Filing Pending / Under Review
REDACTED VERSION of 138 Joint Claim Construction Brief, by Genzyme Corporation. (Vavala, Donald) Modified on 4/23/2026 (nms). (Entered: 04/23/2026)
Entry #160 • 2026-04-23 Document →

Docket Entries

(421 total)
Pleading / Complaint

COMPLAINT with Jury Demand against Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc. (Filing fee $ 405, receipt number ADEDC-4462061) - filed by Genzyme Corporation. (Attachments: # 1 Exhibits A-D, # 2 Exhibits E-H, # 3 Civil Cover Sheet)(oam) Modified on 7/31/2024 (nms). (Entered: 07/29/2024)

Entry #1 • 2024-07-26
1
Pleading / Complaint

COMPLAINT with Jury Demand against Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc. (Filing fee $ 405, receipt number ADEDC-4462061) - filed by Genzyme Corporation. (Attachments: # 1 Exhibits A-D, # 2 Exhibits E-H, # 3 Civil Cover Sheet)(oam) Modified on 7/31/2024 (nms). (Entered: 07/29/2024)

Entry #1 • 2024-07-26
2
Pleading / Complaint

COMPLAINT with Jury Demand against Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc. (Filing fee $ 405, receipt number ADEDC-4462061) - filed by Genzyme Corporation. (Attachments: # 1 Exhibits A-D, # 2 Exhibits E-H, # 3 Civil Cover Sheet)(oam) Modified on 7/31/2024 (nms). (Entered: 07/29/2024)

Entry #1 • 2024-07-26
2
Pleading / Complaint

COMPLAINT with Jury Demand against Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc. (Filing fee $ 405, receipt number ADEDC-4462061) - filed by Genzyme Corporation. (Attachments: # 1 Exhibits A-D, # 2 Exhibits E-H, # 3 Civil Cover Sheet)(oam) Modified on 7/31/2024 (nms). (Entered: 07/29/2024)

Entry #1 • 2024-07-26
2

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (oam) (Entered: 07/29/2024)

Entry #2 • 2024-07-26
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc